AI Article Synopsis
Article Abstract
Objective: To examine trends in the direct acting antiviral (DAA) uptake in a multi-state Medicaid population with hepatitis C virus (HCV) prior to and after ledipasvir/sofosbuvir (LDV/SOF) approval and changes in prior authorization (PA) requirements.
Data Sources: Analyses utilized enrollment, medical, and pharmacy claims in four states, December 2013-December 2017.
Study Design: An interrupted time series examined trends in uptake (1+ claim for a DAA) before and after two events: LDV/SOV approval (October 2014) and lifting of PA requirements for 40% of members (July 2016). Analyses were also performed in subgroups defined by the number and dates of change in PA requirements in members' Medicaid plans.
Data Collection/extraction Methods: Members aged 18-64 years with an ICD code for HCV were included in the sample from diagnosis date until treatment initiation or Medicaid disenrollment.
Principal Findings: The annual sample size ranged from 38,302 to 45,005 with approximately 30% ages 18-34 years and 40% female. In December 2013, 0.08% was treated, rising to 0.74% in December 2017 (p < 0.001). Uptake increased from 0.34%/month in October 2014 to 0.70%/month after LDV/SOF approval, (p < 0.001), and increased relative to the pre-LDV/SOV trend through June 2016 (p = 0.04). Uptake increased to 1.18%/month after PA change, (p < 0.001) and remained flat through 2017 (p = 0.64). Cumulatively, 20.1% were treated by December 2017. In plans with few/no requirements through 2017, uptake increased to 1.19%/month after LDV/SOF approval (p < 0.001) and remained flat through 2017 (p = 0.11), with 22.2% cumulatively treated. Among plans that lifted PA requirements from three to zero in mid-2016, uptake did not increase after LDV/SOF approval (p = 0.36) but did increase to 1.41%/month (p < 0.001) after PA change, with 18.1% cumulatively treated.
Conclusions: HCV Treatment increased through 2017. LDV/SOF approval and lifting PA requirements led to an increase in uptake followed by flat monthly utilization. Cumulative uptake was higher in plans with few/no PA requirements relative to those with three requirements through mid-2016.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9643082 | PMC |
| http://dx.doi.org/10.1111/1475-6773.13994 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Emerging and characterization of a novel fowl adenovirus 4 strain with open reading frame 19 (ORF19) in diseased chickens from China.
Poult Sci
December 2024
Institute of Pathogen Biology and Immunology, College of Biology, Hunan Provincial Key Laboratory of Medical Virology, Hunan University, Changsha 410082, China. Electronic address:
The highly virulent genotype fowl adenovirus 4 (FAdV-4), associated with severe hydropericardium hepatitis syndrome (HHS) in poultry from China, is characterized by a large deletion of 1966 bp (1966-del), including losses of ORF19 and ORF27. However, how this virus originated remains unclear. In this study, a novel FAdV-4 strain, HNU-XXY-2019, from diseased chickens, which has a genome size of 45669 bp and is approximately 1966 bp longer than the known FAdV-4 genome from China, was isolated and characterized.
View Article and Find Full Text PDFHBV-Induced Carcinogenesis: Mechanisms, Correlation With Viral Suppression, and Implications for Treatment.
Liver Int
January 2025
NYU Langone Health, New York, New York, USA.
Background: Chronic hepatitis B virus (HBV) infection is a common but underdiagnosed and undertreated health condition and is the leading cause of hepatocellular carcinoma (HCC) worldwide. HBV (rated a Grade 1 carcinogen by the International Agency for Research on Cancer) drives the transformation of hepatocytes in multiple ways by inducing viral DNA integrations, genetic dysregulation, chromosomal translocations, chronic inflammation, and oncogenic pathways facilitated by some HBV proteins. Importantly, these mechanisms are active throughout all phases of HBV infection.
View Article and Find Full Text PDFPgRNA closely correlates to cytokine profile in HBeAg-positive pregnant women undergoing prophylactic antiviral intervention.
Front Immunol
December 2024
Department of Infectious Diseases, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Background: Previous studies primarily focused on the effects of ALT and virology, but there is a lack of research on the correlations of HBcrAg and pgRNA, two novel virologic markers, with immunological parameters in pregnant women with CHB undergoing prophylactic antiviral intervention.
Methods: We conducted a retrospective cohort study involving 28 HBeAg-positive pregnant women with CHB undergoing prophylactic antiviral intervention. Clinical data, virological markers (HBV DNA, HBsAg, HBeAg, HBcrAg and pgRNA) and 28 cytokines were detected at three time points: 24-28 weeks gestation (before prophylactic antiviral intervention), near birth and within 3 months postpartum.
Hepatocellular Carcinoma Developing in a Patient 29 Years After Achieving Sustained Virologic Response for Hepatitis C With Interferon Therapy: A Case Report.
Cureus
November 2024
Department of Radiology, Mito Kyodo General Hospital, Mito, JPN.
We report a case of an 87-year-old female with a ruptured hepatocellular carcinoma (HCC). She presented with sudden epigastric and right upper abdominal pain. The physical examination revealed mild tenderness in the right upper abdomen, a positive Murphy's sign, and no jaundice.
View Article and Find Full Text PDFSpatiotemporal distribution characteristics and impact factors of hepatitis C in Chongqing, China, 2014-2020.
BMJ Open
December 2024
School of Public Health, Chongqing Medical University, Chongqing, China
Objectives: This study aimed to explore the spatial and temporal distribution of hepatitis C and its influencing factors in Chongqing, providing a scientific basis for the relevant departments to formulate targeted preventive measures for the high prevalence of hepatitis C in the region and population.
Design: We collected data on hepatitis C cases in Chongqing (located in the southwest of China) from 2014 to 2020, and analysed the spatiotemporal heterogeneity of hepatitis C incidence in different populations and identified factors that might influence the incidence of hepatitis C by constructing a Bayesian spatiotemporal model.
Settings: The study subjects included clinically diagnosed cases and confirmed cases of hepatitis C with current address in Chongqing and onset date between 1 January 2014 and 31 December 2020.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!